iScience

iScience 由 Elsevier 出版，属中科院综合性期刊大类（2025 升级版2区）。按 OpenAlex 近年发文统计，该刊主要发表 RNA modifications and cancer、SARS-CoV-2 and COVID-19 Research、Immune Cell Function and Interaction 等主题的论文，这 3 个主题约占 17%，主导子领域为 Molecular Biology。（根据 OpenAlex 主题统计与中科院分区数据生成）

iScience is a peer-reviewed journal from Cell Press that provides a platform for original research in the life, physical, earth, sustainability, and health sciences. We aim to fuel interdisciplinary thinking and consider research with significant contribution to a relevant field combined with robust results and underlying methodology. To support transparency in scientific investigation, we consider replication studies and papers describing negative results, provided they offer clear value to the research community. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. At iScience, our mission is to provide a fast-paced peer-review process with exceptional author service. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Out of scope for iScience iScience will no longer consider articles in the following areas:Mendelian Randomization studies without performing two-sample MR analysis, sensitivity analysis, genome-wide significance of the selected SNP, replication analysis in independent cohorts, test for potential confounders, reported study power, and strong experimental validation using original cohorts.Datamining studies using single datasets without experimental validation in original or external cohorts and strong originality, novelty and advance.Single center retrospective studies, except for rare conditions or special populations with strong originality, novelty and advance.Case reports or case-controlled reports.Machine-learning or artificial intelligence methods without benchmarking against similar methods and demonstrated superior performance.Studies investigating natural extracts of any origin without standardization and identification of the active components.Studies investigating the effects of complementary medicine approaches without very strong mechanistic insights and novelty.Network pharmacology studies without extensive experimental validation in physiologically relevant models.Studies implicating the involvement of oxidative stress in biological processes without strong mechanistic insights.Studies investigating biomarkers without external cohort validation in original cohorts or large datasets, and strong originality, novelty and advance.Studies proposing biomarkers, nomograms or decision algorithms in health/life sciences without external cohort validation and strong originality, novelty and advance.Bibliometric analysis of any topic.Qualitative surveys in Health Sciences, or surveys with non-representative number of respondents.Studies generally about increasing tourism, or about tourism trends (unless rooted in scientific insight).Studies generally about productivity improvement in business, education, law, or economics, without rooting in new modelling (with data and code shared) and/or scientific insight.Studies generally about the stock market or predicting trends, without rooting in new modelling (with data and code shared) and/or scientific insight.Research which does not represent an advancement toward improving the conditions of non-human life, heritage, natural resources utilization, and the environment.Studies of complex environmental or social systems which only rely on statistical projections or correlations.

摘自期刊官网 Aims & Scope

研究方向（LetPub）：Multidisciplinary-Multidisciplinary

编委会国家分布：中国大陆 29 位（约 18%）；主要国家 美国 52、中国 29、澳大利亚 10、英国 9、印度 7（共 165 位编委标注了国家） 编委会 ↗出版商官网 · 2026-10-01

中科院期刊分区表

数据库收录

SCIEScopusDOAJLetPub

国际期刊预警名单：各版本均未列入LetPub

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

4.42LetPub · 2026-09-13

影响因子（出版商公布）

4.5出版商官网 · 2026-10-01

CiteScore 2026-06

7.4LetPub · 2026-09-13

CiteScore（出版商公布）

7.4出版商官网 · 2026-10-01

SJR 2026-06

1.36LetPub · 2026-09-13

SNIP 2026-06

1.06LetPub · 2026-09-13

h-index

141OpenAlex · 2026-10-01

i10-index

7,432OpenAlex · 2026-10-01

两年平均被引

4.72OpenAlex · 2026-10-01

自引率

2.2%LetPub · 2026-09-13

Gold OA 文章占比

99.9%LetPub · 2026-09-13

发文规模

年文章数

2,626LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

平均审稿速度（社区反馈）

6 WeeksLetPub · 2026-09-13

投稿到首次决定

6 天出版商官网 · 2026-10-01

投稿到接收

166 天出版商官网 · 2026-10-01

投稿到发表（期刊自报）

约 27 周DOAJ · 2026-10-11

评审方式

单盲同行评审DOAJ

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

• APC 费用说明 ↗DOAJ
• 费用减免政策 ↗DOAJ
• 开放获取声明 ↗DOAJ
• 许可与版权 ↗DOAJ

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Elsevier

出版国家或地区

UNITED STATES

出版语言

English

ISSN

2589-0042

官方链接

• 期刊主页 ↗OpenAlex
• 投稿系统 ↗出版商官网
• 作者指南 ↗DOAJ
• Aims & Scope ↗DOAJ
• 专刊 / 特刊征稿 ↗出版商官网
• APC 费用说明 ↗DOAJ
• 费用减免政策 ↗DOAJ
• 开放获取声明 ↗DOAJ
• 许可与版权 ↗DOAJ
• 评审流程 ↗DOAJ
• 编委会 ↗DOAJ